Market Outline: Asia Pacific Influenza Treatment Market
Influenza is an upper respiratory tract disease and is caused by the influenza virus. Influenza virus is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through the flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhoea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma.
Asia Pacific influenza treatment market was valued at US $ XX Mn and expected to grow at 2.2% Compound Annual Growth Rate (CAGR) from 2018 to 2024.
Increase in the prevalence of influenza coupled with rise in geriatric population in Asia Pacific countries is a key factor drives the growth of Asia Pacific influenza treatment market over the forecast years. Moreover, increase in the R&D for the innovation of newer therapeutics for influenza treatment, government initiations to rise the awareness about influenza vaccine, frequent product launchings, and technological advancements in the disease diagnosis are anticipated to propel the Asia Pacific influenza treatment market over the forecast years. However, lack of required funding, limited opportunities for the production of vaccines, and stringent regulatory policies for new product approvals might hamper the growth of Asia Pacific influenza treatment market.
Asia Pacific influenza treatment market is segmented based on drug class, route of administration, and distribution channel
Based on drug class, market is segmented into the following:
- Anti-viral drugs
Based on the route of administration, market is segmented into the following:
- Anti-viral drugs
- Interferon alfa-2b
Based on the distribution channel, the market is segmented into the following:
- Hospital pharmacies
- Retail pharmacies
Geographically, Asia Pacific influenza market is segmented into Japan, China, India, Australia & New Zealand, ASEAN Countries, South Korea, and Rest of Asia Pacific. Japan influenza treatment market is poised to grow due to rise in prevalence of influenza in Japan, frequent product approvals for the influenza drugs, and rise in awareness about the influenza vaccine are surge the market. China influenza treatment market has a lucrative growth attributed to high awareness about the vaccination among the people, innovation of newer therapeutics, and increase in healthcare expenditure are bolster the market. However, India influenza treatment market is driven by increase in the number of geriatric population, entry of market players into the country, and rise in incidence of the disease are fuel the market over the forecast years.
Some of the players in the Asia Pacific influenza market include:
- AstraZeneca (U.K.)
- Hoffmann-La Roche (Switzerland)
- GlaxoSmithKline Plc. (U.K.)
- Novartis AG (Switzerland)
- Sanofi Pasture (France)
- Protein Sciences Corporation (U.S.)
- Emergent Biosolutions (U.S.)
- BioCryst Pharmaceuticals.Inc. (U.S.)
- Shionogi Inc. (Japan)
- Abbott Laboratories Inc. (U.S.)
Notable Market Developments:
- In March 2018, Japanese pharma company Shionogi launched single-dose flu drug Xofluza (Baloxsvir marboxil) in Japan